Descrizione del progetto
Anticorpi terapeutici per i cani
In Europa, sono sempre di più le persone che possiedono un animale domestico, e il mercato globale che ruota attorno alla loro salute vale più di 10 miliardi di euro. Le attuali terapie per le malattie infiammatorie croniche, tra cui le malattie infiammatorie intestinali, sono costose e inefficaci, e spesso portano all’eutanasia degli animali. Il progetto CAESAR, finanziato dall’UE, fornisce supporto all’azienda tedesca di biotecnologie Adivo con l’obiettivo di sviluppare anticorpi terapeutici per cani per il trattamento del cancro e delle infiammazioni croniche, con la possibilità di espandersi in futuro allo sviluppo di terapie per altre specie. L’azienda ha già sviluppato una libreria sintetica di esposizione fagica (phage display) canina, unica nel suo genere, che permetterebbe di generare anticorpi terapeutici per i cani, con l’obiettivo primario di sintetizzare anticorpi terapeutici specifici nativi per il trattamento delle malattie infiammatorie intestinali.
Obiettivo
Chronic inflammatory diseases in pets such as Inflammatory Bowel Diseases (IBD) are poorly managed causing emotional and financial distress to pet owners. Current therapies are ineffective - they do not relieve pet suffering and lead to the animal being put down. Therapies are also expensive with costs up to €400/month. Antibody therapy for such conditions has long been used in human medicine but has not been sufficiently developed for veterinary medicine and causes an immunogenic response as the antibodies are not species specific. Antibodies need to be adapted which is expensive and causes severe side effects making them an untenable solution at present. Pet ownership in the EU has been on the increase (up by 2million pets since 2016) due to demographic shifts and a greater reliance on pets as companions. The global animal health market is worth > €29Bn growing at a CAGR of 6% with pet health making up 40% of the market. Pet owners spend €3k - €5k/ year on their pet’s health and are willing to pay to ease pet suffering. adivo is a German biotech company specializing in generating species-specific therapeutic antibodies for companion animals. adivo was founded in 2018. The adivo-team aims to address medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in future. adivo has developed CAESAR, the first of a kind synthetic canine phage-display library to generate therapeutic antibodies for dogs. We have developed a complete library from which we can synthesize therapeutic antibodies native to treat IBD. Our solution will overcome the challenges of current therapies and provide an affordable, scalable solution for effective antibody therapy for pets which has been demonstrated in human medicine. We expect to generate out-licensing revenue ≥€15M when we launch the product before royalties and hire 12 people.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- agricultural sciencesanimal and dairy sciencedomestic animals
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
82152 PLANEGG
Germania
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.